613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors
Hui Gan(Austin Hospital), M.J. Millward, Ruth Plummer(National Health Service), Malcolm Ranson(Cancer Research UK Manchester Institute), Gérard Zalcman(Université Claude Bernard Lyon 1), Jolly Mazumdar(Howard Hughes Medical Institute), Sarah P. Blagden(Churchill Hospital), Noelia Nebot(Research Triangle Park Foundation), H.T. Arkenau(Sarah Cannon Research Institute), T. R. J. Evans, K R Auger(Providence College), Ronald A. Fleming(Research Triangle Park Foundation), J.C. Soria, Vijay Peddareddigari(GlaxoSmithKline (United States)), Donald M. Gibson, Shannon Murray
Cited by 3
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
|Nature Medicine|2022|637
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541